Nuzenio Source-attributed brief

Reed Jobs would rather talk about curing cancer than his last name

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing...

TechCrunchยท
AI summary

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing...

What happened

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing...

Why it matters

This tech report matters because top stories can affect public decisions, policy, markets, civic life, and how readers understand the day. It is currently attributed to TechCrunch; readers should open the publisher link for the complete report and latest updates.

Key facts
  • Category: tech
  • Edition: US
  • Fetched: Sun, 12 Jul 2026 01:05:24 GMT
Read original publisher story Open live Nuzenio coverage Source attribution

Nuzenio shows copyright-safe summaries and context. Full reporting stays with the original publisher.